Dimerix licenses DMX-200 to Everest Medicines for Greater China, South Korea and Southeast Asia with $14.1M upfront and up to ~ $466M milestones

Dimerix licenses DMX-200 to Everest Medicines for Greater China, South Korea and Southeast Asia with $14.1M upfront and up to ~ $466M milestones | Raisolo